IFNA1 and COVID-19: Things like reduced IFN production, faulted IFN signaling, pathogenic ISG effectors, and possibly accelerated viral mutation in obesity collectively lead to impaired antiviral ability and extensive cytopathogenic effect induced by uncontrolled SARS-CoV-2 at the early stage of COVID-19.